Matthew T. McEvoy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Matthew T. McEvoy has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Elizabeth L. Seashore
Division of Pediatric Pain, Palliative, and Integrative Medicine and Division of Pediatric Oncology UCSF School of Medicine UCSF Benioff Children's Hospitals San Francisco California USA
2 shared publicationsShondra Clay
School of Interdisciplinary Health Professions College of Health and Human Sciences Northern Illinois University DeKalb Illinois USA
2 shared publications- Adam L. Green
Morgan Adams Foundation Pediatric Brain Tumor Research Program, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado
1 shared publication Amanda Brown
Division of Rheumatology, Department of Pediatrics, University of Arkansas for Medical Sciences, Arkansas Children’s Hospital, Little Rock, AR
1 shared publication- Amy L. Dimachkieh
Department of Otolaryngology‐Head and Neck Surgery Baylor College of Medicine Houston Texas USA
1 shared publication - Anastasia Deeter
Division of Pediatric Hematology/Oncology, Texas Children’s Hospital, Houston, TX 77030, USA
1 shared publication
Latest Publications
- 21 October 2026
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
Elevator Ride
Was not provided for this article.
- 21 October 2026
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
Elevator Ride
Was not provided for this article.
- Open Access
Advance Care Planning for Adolescents and Young Adults with Cancer: A Clinical Review
Adolescents and young adults (AYAs) diagnosed with cancer experience unique psychosocial distress and worse clinical outcomes compared to their younger and older peers. Additionally, the developmental emergence of identity and independence for AYAs—and the effects of oncology therapy on these milestones—adds complexity to communication and medical decision-making among patients and families. Given these circumstances, AYAs require thoughtful approaches for advance care planning (ACP). In many cases, specialty palliative care (SPC) teams can provide an extra layer of support to both patients and families as well as primary oncology teams in navigating ACP and ensuring goal-concordant care. While some adult studies have recently questioned the effectiveness of standard ACP methods, other new investigations specifically in the AYA cancer population have demonstrated multifaceted benefits. With the understudied nature of both ACP techniques and the AYA population in general and the constant evolution of communication preferences in the digital technology era, pediatric oncology clinicians may be unsure of current best practices for how to guide their older patients during conversations about their illness. We aim to review the most recent evidence regarding ACP for AYAs with cancer, with an emphasis on describing practical bedside tools and the advantages of collaborating with SPC teams to promote optimal outcomes.
Open AccessAdvance Care Planning for Adolescents and Young Adults with Cancer: A Clinical Review
Adolescents and young adults (AYAs) diagnosed with cancer experience unique psychosocial distress and worse clinical outcomes compared to their younger and older peers. Additionally, the developmental emergence of identity and independence for AYAs—and the effects of oncology therapy on these milestones—adds complexity to communication and medical decision-making among patients and families. Given these circumstances, AYAs require thoughtful approaches for advance care planning (ACP). In many cases, specialty palliative care (SPC) teams can provide an extra layer of support to both patients and families as well as primary oncology teams in navigating ACP and ensuring goal-concordant care. While some adult studies have recently questioned the effectiveness of standard ACP methods, other new investigations specifically in the AYA cancer population have demonstrated multifaceted benefits. With the understudied nature of both ACP techniques and the AYA population in general and the constant evolution of communication preferences in the digital technology era, pediatric oncology clinicians may be unsure of current best practices for how to guide their older patients during conversations about their illness. We aim to review the most recent evidence regarding ACP for AYAs with cancer, with an emphasis on describing practical bedside tools and the advantages of collaborating with SPC teams to promote optimal outcomes.
- Open Access
- 15 March 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (5) , e70199
Clinical Course and Impact of Breaks in Therapy for Children With Relapsed/Refractory Solid Tumors
Introduction: Pediatric relapsed or refractory (R/R) solid tumors carry a dismal prognosis, and postrelapse patient experiences are not well described. We present postrelapse outcomes, including number of R/R events and subsequent therapy regimens. We analyze whether breaks (>30 days) between events and subsequent therapies affect survival and the associated decision‐making rationales. Methods: We reviewed data for patients with R/R extracranial solid tumors treated at Texas Children's Hospital between 2005 and 2023. Descriptive analysis was performed along with univariate chi‐square and independent sample t ‐tests. Cox regression analysis was used to evaluate postevent survival (PES). Results: Of the 466 patients (female: 47%; median age: 8.7 years), most common diagnoses were neuroblastoma (21.5%), rhabdomyosarcoma (19.1%), and osteosarcoma (16.1%). Patients had a median of 3 (interquartile range [IQR]: 1–4) R/R events with a median of 93 (IQR: 52–200) days between events. Of 438 patients who received ≥1 postevent therapy regimen, 116 (26.5%) experienced ≥1 break. Reasons for breaks varied evenly between intentional/goal‐concordant and undesired delays. Median PES for all patients was 12.9 (IQR: 5.8–31.4) months. In a multivariable Cox regression model, taking a >30‐day break in disease‐directed therapy was associated with prolonged PES (hazard ratio 0.58 [95% CI 0.45–0.76], p < 0.001). Conclusions: Most children with R/R solid tumors experience multiple events and therapy regimens without a break. Presence of a >30‐day break did not negatively affect survival, implying that time between therapy regimens can safely be offered to select patients to promote quality of life and thoughtful decision‐making, without compromising survival.
- 15 March 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (5) , e70199
Open AccessClinical Course and Impact of Breaks in Therapy for Children With Relapsed/Refractory Solid Tumors
Introduction: Pediatric relapsed or refractory (R/R) solid tumors carry a dismal prognosis, and postrelapse patient experiences are not well described. We present postrelapse outcomes, including number of R/R events and subsequent therapy regimens. We analyze whether breaks (>30 days) between events and subsequent therapies affect survival and the associated decision‐making rationales. Methods: We reviewed data for patients with R/R extracranial solid tumors treated at Texas Children's Hospital between 2005 and 2023. Descriptive analysis was performed along with univariate chi‐square and independent sample t ‐tests. Cox regression analysis was used to evaluate postevent survival (PES). Results: Of the 466 patients (female: 47%; median age: 8.7 years), most common diagnoses were neuroblastoma (21.5%), rhabdomyosarcoma (19.1%), and osteosarcoma (16.1%). Patients had a median of 3 (interquartile range [IQR]: 1–4) R/R events with a median of 93 (IQR: 52–200) days between events. Of 438 patients who received ≥1 postevent therapy regimen, 116 (26.5%) experienced ≥1 break. Reasons for breaks varied evenly between intentional/goal‐concordant and undesired delays. Median PES for all patients was 12.9 (IQR: 5.8–31.4) months. In a multivariable Cox regression model, taking a >30‐day break in disease‐directed therapy was associated with prolonged PES (hazard ratio 0.58 [95% CI 0.45–0.76], p < 0.001). Conclusions: Most children with R/R solid tumors experience multiple events and therapy regimens without a break. Presence of a >30‐day break did not negatively affect survival, implying that time between therapy regimens can safely be offered to select patients to promote quality of life and thoughtful decision‐making, without compromising survival.
- Open Access
- 1 October 2025
- Published by UT MD Anderson Cancer Center Research Medical Library in Advances in Cancer Education and Quality Improvement
- Vol. 1 (2) , 5
Unremitting
A poem that describes the different stages of a patient’s cancer experience through metaphor and word play, exploring the myriad difficulties while also maintaining hope.
- 1 October 2025
- Published by UT MD Anderson Cancer Center Research Medical Library in Advances in Cancer Education and Quality Improvement
- Vol. 1 (2) , 5
Open AccessUnremitting
A poem that describes the different stages of a patient’s cancer experience through metaphor and word play, exploring the myriad difficulties while also maintaining hope.
- 3 May 2025
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 71 (6) , e752-e754
Presence
- 3 May 2025
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 71 (6) , e752-e754
Presence
- 19 February 2025
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 47 (3) , 140-143
A Unique Case of Gross Hematuria in a Patient With Ewing Sarcoma
The standard therapy for Ewing sarcoma, the second most common bone tumor in children, includes alkylating agents such as ifosfamide and cyclophosphamide. One common adverse side effect of such agents is hemorrhagic cystitis, which typically presents with hematuria. We present the case of a patient with Ewing sarcoma who developed persistent gross hematuria followed by severe acute kidney injury while receiving chemotherapy. After interdisciplinary evaluation, including renal biopsy and assessment for lupus nephritis, a unique underlying diagnosis of immune-complex glomerulonephritis was determined. Herein, we discuss this novel case, including stepwise diagnostic evaluation, multimodal therapy, chemotherapy adjustments, and long-term disease monitoring.
- 19 February 2025
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 47 (3) , 140-143
A Unique Case of Gross Hematuria in a Patient With Ewing Sarcoma
The standard therapy for Ewing sarcoma, the second most common bone tumor in children, includes alkylating agents such as ifosfamide and cyclophosphamide. One common adverse side effect of such agents is hemorrhagic cystitis, which typically presents with hematuria. We present the case of a patient with Ewing sarcoma who developed persistent gross hematuria followed by severe acute kidney injury while receiving chemotherapy. After interdisciplinary evaluation, including renal biopsy and assessment for lupus nephritis, a unique underlying diagnosis of immune-complex glomerulonephritis was determined. Herein, we discuss this novel case, including stepwise diagnostic evaluation, multimodal therapy, chemotherapy adjustments, and long-term disease monitoring.
- Open Access
- 13 April 2023
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 65 (5) , e592
End-of-Life Outcomes in Children with Relapsed/Refractory Solid Tumors: A Single-Center Study (Sch425)
- 13 April 2023
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 65 (5) , e592
Open AccessEnd-of-Life Outcomes in Children with Relapsed/Refractory Solid Tumors: A Single-Center Study (Sch425)
- 29 December 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (3) , e30181
Management of nutritional iron deficiency anemia for young children in the emergency department
Background: Guidelines for young children with nutritional iron deficiency anemia (IDA) presenting to the emergency department (ED) are lacking, leading to variability in care. We aimed to standardize management of these patients through the development and implementation of an evidence‐based algorithm using quality improvement methodology.Procedure: Baseline data of the target population (n = 42; 60% male; median age 22.5 months, median hemoglobin 5.3 g/dl) identified variability across four key measures of clinical management: laboratory evaluation, therapy choice, therapy administration, and patient disposition. Literature review and consensus from pediatric hematology providers informed a draft algorithm that was refined in an iterative multidisciplinary process. From September 2020 to June 2021, we aimed to increase IDA management per the algorithm by ≥20% relative to baseline for the four key outcome measures using sequential Plan‐Do‐Study‐Act (PDSA) cycles. Process measures focusing on provider communication/documentation and balancing measures involving efficiency and therapy‐related adverse events were assessed concurrently.Results: Thirty‐five patients were evaluated among four PDSA cycles and shared similar characteristics as the baseline population. Improvements of ≥20% above baseline adherence levels or 100% adherence were achieved for all outcome measure across four PDSA cycles. Adherence to recommended laboratory evaluation improved from 43 (baseline) to 71%, therapy choice from 78 to 100%, therapy administration from 50 to 83%, and disposition from 85 to 100%. ED length of stay remained stable.Conclusions: Implementation of a standardized algorithm for young children with nutritional IDA in the ED increased adherence to evidence‐based patient care.
- 29 December 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (3) , e30181
Management of nutritional iron deficiency anemia for young children in the emergency department
Background: Guidelines for young children with nutritional iron deficiency anemia (IDA) presenting to the emergency department (ED) are lacking, leading to variability in care. We aimed to standardize management of these patients through the development and implementation of an evidence‐based algorithm using quality improvement methodology.Procedure: Baseline data of the target population (n = 42; 60% male; median age 22.5 months, median hemoglobin 5.3 g/dl) identified variability across four key measures of clinical management: laboratory evaluation, therapy choice, therapy administration, and patient disposition. Literature review and consensus from pediatric hematology providers informed a draft algorithm that was refined in an iterative multidisciplinary process. From September 2020 to June 2021, we aimed to increase IDA management per the algorithm by ≥20% relative to baseline for the four key outcome measures using sequential Plan‐Do‐Study‐Act (PDSA) cycles. Process measures focusing on provider communication/documentation and balancing measures involving efficiency and therapy‐related adverse events were assessed concurrently.Results: Thirty‐five patients were evaluated among four PDSA cycles and shared similar characteristics as the baseline population. Improvements of ≥20% above baseline adherence levels or 100% adherence were achieved for all outcome measure across four PDSA cycles. Adherence to recommended laboratory evaluation improved from 43 (baseline) to 71%, therapy choice from 78 to 100%, therapy administration from 50 to 83%, and disposition from 85 to 100%. ED length of stay remained stable.Conclusions: Implementation of a standardized algorithm for young children with nutritional IDA in the ED increased adherence to evidence‐based patient care.
- 1 October 2022
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 64 (4) , e227-e229
A Holy Moment
- 1 October 2022
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 64 (4) , e227-e229
A Holy Moment
- 14 September 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (3) , e29972
A novel case of malignant ossifying fibromyxoid tumor with a BCOR internal tandem duplication in a child
- 14 September 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (3) , e29972
A novel case of malignant ossifying fibromyxoid tumor with a BCOR internal tandem duplication in a child